|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Voyager Therapeutics, Inc. (VYGR) |
|
|
$3.20 0.00 (0.00%) as of 4:30 Wed 7/2
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
37,470,000 |
Market
Cap: |
119.90(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$2.73 - $9.27 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
77,515 |
90,014 |
161,592 |
Total Sell Value |
$0 |
$322,474 |
$394,113 |
$978,771 |
Total People Sold |
0 |
5 |
5 |
6 |
Total Sell Transactions |
0 |
11 |
13 |
25 |
End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pfreundschuh Peter P. |
Chief Financial Officer |
|
2024-02-21 |
4 |
S |
$7.46 |
$28,079 |
D/D |
(3,764) |
175,669 |
|
1% |
|
Sandrock Alfred |
President and CEO |
|
2024-02-21 |
4 |
S |
$7.46 |
$97,226 |
D/D |
(13,033) |
334,954 |
|
1% |
|
Swartz Robin |
Chief Operating Officer |
|
2024-02-21 |
4 |
S |
$7.45 |
$29,547 |
D/D |
(3,966) |
118,361 |
|
1% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2024-02-21 |
4 |
S |
$7.47 |
$25,137 |
D/D |
(3,365) |
87,627 |
|
1% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2024-02-20 |
4 |
S |
$7.68 |
$4,623 |
D/D |
(602) |
90,992 |
|
-4% |
|
Sandrock Alfred |
President and CEO |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
130,000 |
347,987 |
|
- |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
38,500 |
91,594 |
|
- |
|
Swartz Robin |
Chief Operating Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
122,327 |
|
- |
|
Fahey Sandell Jacquelyn |
Chief Legal Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
31,000 |
92,000 |
|
- |
|
Pfreundschuh Peter P. |
Chief Financial Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
179,433 |
|
- |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2024-01-17 |
4 |
S |
$7.18 |
$9,090 |
D/D |
(1,266) |
53,094 |
|
-10% |
|
Swartz Robin |
Chief Operating Officer |
|
2024-01-17 |
4 |
S |
$7.15 |
$18,182 |
D/D |
(2,543) |
72,327 |
|
-10% |
|
Pfreundschuh Peter P. |
Chief Financial Officer |
|
2023-10-03 |
4 |
S |
$6.99 |
$94,833 |
D/D |
(13,567) |
149,433 |
|
-9% |
|
Fahey Sandell Jacquelyn |
Chief Legal Officer |
|
2023-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
61,000 |
61,000 |
|
- |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-09-15 |
4 |
AS |
$8.16 |
$85,680 |
D/D |
(10,500) |
54,360 |
|
-4% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-09-15 |
4 |
OE |
$2.85 |
$14,250 |
D/D |
5,000 |
64,860 |
|
- |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-07-06 |
4 |
AS |
$10.80 |
$59,400 |
D/D |
(5,500) |
59,860 |
|
-40% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-06-30 |
4 |
AS |
$11.41 |
$57,050 |
D/D |
(5,000) |
65,360 |
|
-40% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-06-30 |
4 |
OE |
$2.85 |
$14,250 |
D/D |
5,000 |
70,360 |
|
- |
|
Swartz Robin |
Chief Operating Officer |
|
2023-04-03 |
4 |
S |
$7.83 |
$9,858 |
D/D |
(1,259) |
71,617 |
|
-15% |
|
Sandrock Alfred |
President and CEO |
|
2023-04-03 |
4 |
S |
$7.83 |
$58,232 |
D/D |
(7,437) |
214,618 |
|
-15% |
|
Swartz Robin |
Chief Operating Officer |
|
2023-03-20 |
4 |
AS |
$7.76 |
$28,355 |
D/D |
(3,654) |
72,876 |
|
17% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-03-20 |
4 |
AS |
$7.76 |
$17,018 |
D/D |
(2,193) |
65,360 |
|
17% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2023-03-20 |
4 |
AS |
$7.76 |
$34,222 |
D/D |
(4,410) |
102,200 |
|
17% |
|
Swartz Robin |
Chief Operating Officer |
|
2023-03-15 |
4 |
S |
$8.20 |
$126,059 |
D/D |
(15,373) |
76,530 |
|
-12% |
|
70 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|